Skip to main content

and
  1. Article

    Open Access

    Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial

    The antiangiogenic agent apatinib has been shown to clinically improve responses to immune checkpoint inhibitors in several cancer types. Patients with N3 nasopharyngeal carcinoma have a high risk of distant m...

    Hu Liang, Yao-Fei Jiang, Guo-Ying Liu, Lin Wang, Jian-Wei Wang in Nature Communications (2024)